Response to Primary and Booster Vaccination With 10-valent Pneumococcal Nontypeable Haemophilus influenzae Protein D Conjugate Vaccine in Korean Infants
Authors:
- Chang-Hwi KimChang-Hwi Kim
- Jung Soo KimJKJung Soo Kim
- Sung-Ho ChaSCSung-Ho Cha
- Kwang-Nam KimKKKwang-Nam Kim
- Jong-Duck KimJKJong-Duck Kim
- Kyung Yil LeeKyung Yil Lee
- Hwang Min KimHKHwang Min Kim
- Jong-Hyun KimJKJong-Hyun Kim
- Sang HyukSHSang Hyuk
- Jung-Yun HongJHJung-Yun Hong
- Su Eun ParkSPSu Eun Park
- Yun-Kyung KimYun-Kyung Kim
- 1 December 2011
- journal article
- research article
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 30 (12) , e235-e243
Abstract
This randomized single-blind study in Korea evaluated noninferiority of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) versus the 7-valent pneumococcal conjugate vaccine (7vCRM) when both were coadministered with H. influenzae type b (Hib) conjugate vaccine, as opposed to coadministration with diphtheria-tetanus-acellular pertussis-based combination vaccines in previous studies. Infants received 3 primary doses at 2, 4, and 6 months and a booster dose at 12 to 18 months of PHiD-CV (N = 374) or 7vCRM (N = 129), both coadministered with Hib vaccine. Immune responses were measured 1 month postdose 3 and postbooster using 22F-inhibition enzyme-linked immunosorbent assay and functional opsonophagocytic activity assay. PHiD-CV-induced antibody responses against each of the vaccine pneumococcal serotypes and protein D. Noninferiority to 7vCRM was demonstrated for all 10 PHiD-CV serotypes in terms of percentages of subjects reaching an antibody concentration ≥0.2 μg/mL after primary vaccination. Postprimary and postbooster, percentages of subjects with antibody concentration ≥0.2 μg/mL or opsonophagocytic activity titer ≥8 were generally consistent between groups for each pneumococcal serotype common to both vaccines. The safety and reactogenicity profiles of PHiD-CV and 7vCRM were generally comparable after both primary and booster vaccination. In this Korean study, 3-dose PHiD-CV priming followed by a booster dose was immunogenic for all 10 vaccine pneumococcal serotypes and protein D. Noninferiority to 7vCRM in terms of enzyme-linked immunosorbent assay threshold responses postpriming was demonstrated. The safety and reactogenicity profiles of both vaccines when coadministered with Hib vaccine were generally comparable.Keywords
This publication has 32 references indexed in Scilit:
- SAFETY AND IMMUNOGENICITY OF A BOOSTER DOSE OF THE 10-VALENT PNEUMOCOCCAL NONTYPEABLE HAEMOPHILUS INFLUENZAE PROTEIN D CONJUGATE VACCINE COADMINISTERED WITH DTPW-HBV/HIB AND POLIOVIRUS VACCINESThe Pediatric Infectious Disease Journal, 2011
- Antimicrobial Resistance in Haemophilus influenzae Respiratory Tract Isolates in Korea: Results of a Nationwide Acute Respiratory Infections SurveillanceAntimicrobial Agents and Chemotherapy, 2010
- Estimating the direct impact of new conjugate vaccines against invasive pneumococcal diseaseVaccine, 2009
- Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trialsThe Lancet, 2009
- Immunogenicity of a 2-Dose Priming and Booster Vaccination With the 10-Valent Pneumococcal Nontypeable Haemophilus influenzae Protein D Conjugate VaccineThe Pediatric Infectious Disease Journal, 2009
- Immunogenicity of the 10-Valent Pneumococcal Non-typeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) Compared to the Licensed 7vCRM VaccineThe Pediatric Infectious Disease Journal, 2009
- The 10-Valent Pneumococcal Non-typeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) Coadministered With DTPw-HBV/Hib and Poliovirus Vaccines: Assessment of ImmunogenicityThe Pediatric Infectious Disease Journal, 2009
- Safety and Reactogenicity of the 10-Valent Pneumococcal Non-typeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) When Coadministered With Routine Childhood VaccinesThe Pediatric Infectious Disease Journal, 2009
- Streptococcus pneumoniaeSerotype 19A in Children, South KoreaEmerging Infectious Diseases, 2008
- High Prevalence of Antimicrobial Resistance among Clinical Streptococcus pneumoniae Isolates in Asia (an ANSORP Study)Antimicrobial Agents and Chemotherapy, 2004